Corvus Pharmaceuticals, Inc. Proceeds from Sale of Debt Securities, Available-for-sale
Corvus Pharmaceuticals, Inc. (CRVS) reported Proceeds from Sale of Debt Securities, Available-for-sale of $1.01 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-03-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt · last filed 2023-03-28
- Corvus Pharmaceuticals, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2020-12-31 was $0.00.
- Corvus Pharmaceuticals, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2020-09-30 was $0.00.
- Corvus Pharmaceuticals, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2020-06-30 was $0.00.
- Corvus Pharmaceuticals, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2020-03-31 was $1.01M.
- Corvus Pharmaceuticals, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2020 was $1.01M.
- Corvus Pharmaceuticals, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2016 was $4.20M.
| Period end | Proceeds from Sale of Debt Securities, Available-for-sale 3 month | Proceeds from Sale of Debt Securities, Available-for-sale 6 month | Proceeds from Sale of Debt Securities, Available-for-sale 9 month | Proceeds from Sale of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $0.00 derived: sum of 2 quarters · filed 2023-03-28 | $0.00 derived: sum of 3 quarters · filed 2023-03-28 | $1.01M 10-K · filed 2023-03-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $0.00 derived: sum of 2 quarters · filed 2021-11-01 | $1.01M 10-Q · filed 2021-11-01 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $1.01M 10-Q · filed 2021-08-02 | ||
| 2020-03-31 | $1.01M 10-Q · filed 2021-04-29 | |||
| 2016-12-31 | $4.20M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |